Cybin is a clinical-stage biopharmaceutical company pioneering the development of innovative psychedelic-based therapeutics to address mental health challenges. With a robust research pipeline, Cybin is advancing breakthrough treatments such as CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT molecule targeting generalized anxiety disorder. Headquartered in Toronto, Canada, and operating across North America and Europe, the company combines cutting-edge science, rigorous clinical trials, and a commitment to improving mental healthcare. Founded in 2019, Cybin strives to transform traditional treatment paradigms and offer next-generation solutions for a healthier world.